Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season
- PMID: 27277013
- DOI: 10.2807/1560-7917.ES.2016.21.22.30243
Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season
Abstract
We estimated whether previous episodes of influenza and trivalent influenza vaccination prevented laboratory-confirmed influenza in Navarre, Spain, in season 2013/14. Patients with medically-attended influenza-like illness (MA-ILI) in hospitals (n = 645) and primary healthcare (n = 525) were included. We compared 589 influenza cases and 581 negative controls. MA-ILI related to a specific virus subtype in the previous five seasons was defined as a laboratory-confirmed influenza infection with the same virus subtype or MA-ILI during weeks when more than 25% of swabs were positive for this subtype. Persons with previous MA-ILI had 30% (95% confidence interval (CI): -7 to 54) lower risk of MA-ILI, and those with previous MA-ILI related to A(H1N1)pdm09 or A(H3N2) virus, had a, respectively, 63% (95% CI: 16-84) and 65% (95% CI: 13-86) lower risk of new laboratory-confirmed influenza by the same subtype. Overall adjusted vaccine effectiveness in preventing laboratory-confirmed influenza was 31% (95% CI: 5-50): 45% (95% CI: 12-65) for A(H1N1)pdm09 and 20% (95% CI: -16 to 44) for A(H3N2). While a previous influenza episode induced high protection only against the same virus subtype, influenza vaccination provided low to moderate protection against all circulating subtypes. Influenza vaccine remains the main preventive option for high-risk populations.
Keywords: Influenza; case control study; influenza vaccine; influenza-like illness; vaccine effectiveness.
Similar articles
-
Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.Euro Surveill. 2016;21(7):pii=30139. doi: 10.2807/1560-7917.ES.2016.21.7.30139. Euro Surveill. 2016. PMID: 26924024
-
Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.Euro Surveill. 2014 Feb 13;19(6):20701. doi: 10.2807/1560-7917.es2014.19.6.20701. Euro Surveill. 2014. PMID: 24556348
-
Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.Hum Vaccin Immunother. 2015;11(7):1626-33. doi: 10.1080/21645515.2015.1038002. Hum Vaccin Immunother. 2015. PMID: 25996366 Free PMC article.
-
Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies.J Infect Dis. 2018 Feb 14;217(5):731-741. doi: 10.1093/infdis/jix632. J Infect Dis. 2018. PMID: 29220496
-
A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries.Hum Vaccin Immunother. 2016 Apr 2;12(4):993-1002. doi: 10.1080/21645515.2015.1111494. Epub 2016 Feb 18. Hum Vaccin Immunother. 2016. PMID: 26890005 Free PMC article. Review.
Cited by
-
Chronic obstructive pulmonary disease and influenza vaccination effect in preventing outpatient and inpatient influenza cases.Sci Rep. 2022 Mar 22;12(1):4862. doi: 10.1038/s41598-022-08952-0. Sci Rep. 2022. PMID: 35318406 Free PMC article.
-
Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16.Euro Surveill. 2018 Oct;23(43):1700732. doi: 10.2807/1560-7917.ES.2018.23.43.1700732. Euro Surveill. 2018. PMID: 30376915 Free PMC article.
-
The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.Epidemiology. 2020 Jan;31(1):43-64. doi: 10.1097/EDE.0000000000001116. Epidemiology. 2020. PMID: 31609860 Free PMC article.
-
Costs associated with influenza-related hospitalization in the elderly.Hum Vaccin Immunother. 2017 Feb;13(2):412-416. doi: 10.1080/21645515.2017.1264829. Epub 2016 Dec 7. Hum Vaccin Immunother. 2017. PMID: 27925855 Free PMC article.
-
After the Pandemic: New Responsibilities.Public Health Ethics. 2021 May 17;14(2):120-133. doi: 10.1093/phe/phab008. eCollection 2021 Jul. Public Health Ethics. 2021. PMID: 34646354 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical